REGN•benzinga•
9 Analysts Have This to Say About Regeneron Pharmaceuticals
Summary
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga